Navigation Links
FDA Approval for Lung Cancer Treatment -Avastin Along with Chemotherapy

The FDA has approved the drug bevacizumab (Avastin) for first time treatment of advanced lung cancer in conjunction with chemotherapy. // This comes after a large randomised study on lung cancer patients led by Dr.Alan Sandler, lung cancer specialist and director of Thoracic Oncology at Vanderbilt-Ingram Cancer Center.

Nearly 900 patients with non-small cell lung cancer (NSCLC) were tested during the trial. None of them had received any previous chemotherapy. Half were given Avastin along with standard chemotherapy drugs while the others were given chemotherapy alone. The study revealed that patients on Avastin survived an average of two months longer than the usual one year survival rate.

Though this does not sound wonderful, it is important to bear in mind that the results were based on average reactions. In some people the survival was even longer, while in others the tumours shrunk and disappeared. However there was no response in some patients.

Bevacizumab is a targeted drug, which means that it does not attack non-cancerous cells. It acts by stopping development of new blood vessels, which supply the tumours. The side effects are generally mild. However a unique and serious one is bleeding from the primary tumour, since the drug acts on the blood vessels; this has to be addressed.

Dr. Sandler is hopeful that the drug will prove path breaking and lead to better survival rates and also to more patients being cured if the disease is caught early. As NSCLC is the most common form of lung cancer in the US, this is encouraging news indeed.

Page: 1

Related medicine news :

1. Approval for DNA test to detect cystic fibrosis
2. Vaccine For Cervical Cancer Awaits Approval
3. WHO Gives Its Approval For Bird Flu Test Kit
4. FDA Gives Its Approval For Inhaler
5. RotaTeq Gets US Approval
6. Better Communication With FDA Could Speed Up Approval Of New Drugs
7. Nerve Stimulator for Depression Though Not Effective Was Given Approval
8. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
9. Global Education Net Pvt Medical College Gets MCI Approval
10. Approval of Drugs for the Treatment of Late-Stage Cancer
11. Lupin Gets USFDA Approval For Quinapril Tablets
Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... ... process to promote standards of excellence for the field of eating disorders, announces ... 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
Breaking Medicine Technology: